EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary
September 11, 2020
Earnings Call Speaker Segments
Operator
operatorGood afternoon. I'm the conference operator at Chorus Call. Thanks for being with us, and welcome to El.En.'s First Half 2020 Results Conference Call. <<operator_script>> Right now, I'll hand things over to Ms. Bianca Fersini from Polytems HIR. Madam, the floor is yours.
Bianca Fersini Mastelloni
unknownThanks, Samat, and good afternoon or good morning, everyone, and thanks for being with us. Joining me on this call are Andrea Cangioli, EL.En.'s Managing Director, and Enrico Romagnoli, El.En.'s Chief Financial Officer and Investor Relator. Before we start, please be aware that management will make certain remarks on this conference call regarding future expectations, plans and prospects, as well as forward-looking statements. Some statements on this call — including those that address the company's beliefs, plans, objectives, estimates or expectations concerning possible future results or events — are forward-looking statements. Forward-looking statements carry known or unknown risks, including general, economic and business conditions as well as conditions in the industry where we operate, and they may be affected if our assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance or achievements could differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation regarding the content, nor to update the forward-looking statements to reflect events or circumstances that may arise after today's date. Now let me bring Andrea Cangioli onto the call. Go ahead, Andrea.
Andrea Cangioli
executiveThank you, Bianca, and good morning to everyone — good afternoon as well — and thanks for being on this conference call following the publication of our 6-month financial reports. We're speaking to you from our facilities in Florence, where since the middle of August all of our staff have been back at work full-time. That comes after roughly 4 months of heavy use of the payroll protection schemes, the so-called Cassa Integrazione, which we were forced to bring in because demand fell suddenly as a result of the COVID pandemic. Our facilities, along with every practice across the El.En. Group, are safe workplaces, since we put in place all the measures required to safeguard our employees' health and safety. A number of them continue to work remotely so as to limit physical contact, yet we can say the pandemic no longer has any effect on our internal processes. That is clearly welcome news, a signal of the recovery now underway, moving on from the bleakest period of the lockdowns toward the normal situation we had been enjoying during the opening weeks of the year. The 6-month financial results, which Enrico and I will walk you through in detail shortly, and which, to put it as briefly as possible, reveal a 13.8% drop in revenues along with a steeper 44.4% fall in EBIT, with the EBIT margin declining to 5.7%.
Andrea Cangioli
executiveThose figures—the financial numbers—actually reflect a trend that, because of how the pandemic hit during this 6-month period, came out very uneven across the different months. At the starting signal of the year, every one of our businesses took off running faster than ever before. A few days later, though, the pandemic struck China, then Italy, then the rest of the world. In China we had to halt operations entirely for almost 3 months, and in Italy for more than 1 month across the companies in the industrial sector. And that wasn't because of any official decree forcing us—it was the sudden collapse in demand that forced it. The company is also active in the medical market. This very dark cloud abruptly blocked out the very brilliant sunshine of the year's first months, and production and sales levels fell, in certain cases, all the way to 0. In China, February brought 0 production and 0 turnover. In April we had no sales at all in the medical sector and in the professional beauty sector in Italy and France. In Italy, industrial laser system manufacturing, servicing and delivery were blocked for the majority of March and April.
Andrea Cangioli
executiveAfter that, those heavy, dark clouds began to move in, and gradually we began to see sunlight once more. Both how long the store period lasted and how strong the recovery was differed greatly by geographic region and by individual market. To give just a few significant illustrations: in the sheet metal laser-cutting market, demand came back with tremendous vigor, which let capital expense post revenue growth on a 6-month basis and allowed the Chinese business to run again at full production rates across every factory to date. In Japan, where we have a substantial position through our subsidiary operating in the professional aesthetic and spa market, the pandemic's effect was gentler, and we recorded meaningful growth across the 6-month period versus 2019. Sales to the U.S. and in the medical aesthetic business, following a 2-month slowdown, had returned to a satisfying level in July. Sales in Italy's medical market, via our Renaissance distribution network, hit record-level in July and in August. Sales through the Esthelogue network to professional beauty shops likewise returned to a good level following the April stop. All things considered, I would say demand recovery proved stronger than expectation.
Andrea Cangioli
executiveEven though the initial target set for this 2020 was very ambitious, the expectations for bouncing back from the COVID-19 hit were modest. So it makes us glad to observe orders coming in once more and to see customers releasing the backlog orders they had requested we hold. During particular segments and in some months, sales and production came back to the 2019 level and even above it, yet on average we still confront a market that is weaker than it was 12 months ago. This time let me say that the achievements we accomplished in this month make me very proud. Even though these results fall far short of the growth expectation the group held for 2020 at the end of last year, in my view they are very good under the circumstances, and they demonstrate — in the most difficult situation ever faced by the group and by the world economy in the recent past — the great solidity the group has in its structure, its technical structure, its financial structure, its operational structure. We proved in the past our potential to achieve brilliant growth rates, and now we display our ability to resist adverse conditions without sacrificing the potential for future growth. The group owns these characteristics and capabilities first and foremost with its employees.
Andrea Cangioli
executiveTheir response had remarkable depth when it came to keeping essential operations moving, vibrant, and proactive. Even with constrained resources and time, the payroll protection programs, Cassa Integrazione, were used fairly widely. Significant research and development projects reached completion even during the hardest months, which made it possible to introduce new products. Ties with customers were maintained through a creative and diligent social media presence, offering information along with commercial and training events. The logistics and operational structure, along with the auxiliary support functions, labored under difficult circumstances to guarantee deliveries of product and technical support for every one of our customers worldwide. We can rely on this extraordinary asset to get back to outstanding, record-setting results from a financial standpoint as well once conditions around us permit it. Before diving into the financial details, our investment plans under the capacity expansion program were still worth -- I would like to note how those investments are progressing. What I mean is that our investment plans for expanding production capacity still amount to a few million euro of investment during this half year, as we are finishing the plants in Wenzhou, Wuhan, Lin Yi and Torre Annunziata. An additional, unplanned investment is also coming in 2021.
Andrea Cangioli
executiveWe have an opportunity to benefit from the availability of the building next to the new Cutlite Penta facility in Prato. So we locked in the acquisition through a preliminary agreement signed at the start of September; with a down payment of roughly EUR 0.5 million, we will right away be able to utilize this structure to expand our production capacity. And as I said earlier, Cutlite Penta's output and sales volume are truly skyrocketing in this area, and we will then finalize the contract during the first weeks of 2021. I recall that when we presented our structural expansion investment plan, I said that if additional investment were to come in the future, that should be viewed as a positive thing, since it would signal strong demand. And in fact, that is exactly what has happened. And it has also been true for the extra monies we put into the plant. We stand today at approximately EUR 38 million thanks to the chance to expand capacity further in China and at other sites. I would like to hand the call over to Enrico, who will, I mean, walk you through the details of our 6-month financials.
Enrico Romagnoli
executiveThanks, Andrea, and good morning, everyone. As always, I'll walk you through a few points about our financials. We ended the first half of 2020 with consolidated turnover of EUR 163 million, a decline of 13.8% versus the same period a year earlier. Gross margin came in at EUR 59.9 million, 19.5% lower than the EUR 74.4 million recorded on June 2019, reflecting the drop in turnover. The impact on turnover moved from 39.5% down to 36.8%, driven mainly by lower profitability in both sectors because of COVID, although it was larger in industrial than in medical. The sequential decline in gross margin percentage from Q1 to Q2 also reflects industrial carrying more weight in total revenue than medical. Indeed, medical accounted for 73% of total sales in Q1, whereas in Q2 it was 53%. Industrial was 27% in Q1 and 47% in Q2. As a result, gross margin percentage was 43% in Q1 2020 but only 42% in Q2 2020. Operating costs were EUR 16 million, lower than the EUR 21.5 million on June 2019, and their incidence on turnover fell from 11% to 10%.
Enrico Romagnoli
executiveSavings came chiefly from restricted travel and from calling off every fair and congress event, along with a lower volume of activities. Staff costs for June stood at EUR 29.3 million, versus EUR 32.3 million a year earlier. This labor cost decrease, which Andrea already mentioned, stems mainly from government payroll protection programs, including Cassa Integrazione in Italy, and used in France, Germany and Italy as well. EBITDA reached EUR 14.5 million, a decline of 29.7% from EUR 20.6 million in H1 of last year, with an impact on sales of 8.9% versus 10.9%. Amortization and other accruals rose because of the improved potent investments made in 2019, and the bad debt provision went up relative to H1 of 2019 so as to represent in the most balanced way a possible deterioration of some credit positions. Across the first 6 months, total fixed cost, operating cost, staff cost and depreciation fell in overall value, in line with the sales drop, and the impact on sales was around 31% as for H1 2019. EBIT posted a positive balance of EUR 9.3 million, lower than the EUR 16.7 million, with an impact on sales of 5.7% and a reduction of 3% mainly because of the lower gross margin.
Enrico Romagnoli
executivePretax result came in at EUR 8.9 million, with ForEx having a negative effect and associated companies contributing negatively. Net income stood at EUR 6.4 million, versus EUR 10.2 million a year earlier, and the tax rate was 24%, which benefited from a tax reduction granted to the Italian company on IRAP income taxes to address the COVID challenges. The Group's net financial position showed a positive balance of EUR 27.9 million, compared with EUR 61.4 million at the start of the year and EUR 27.5 million at the close of Q1. Roughly EUR 20 million in cash went into acquiring an important minority stake in Penta Laser (Wenzhou) in China. And growth in net working capital absorbed approximately EUR 20 million of liquidity, chiefly because of the rise in the value of inventories. Investment in technical fixed assets was about EUR 5 million, lower than last year, and spending on expanding the production structure is, in fact, below the prior year since most of the new structures are finished or nearing completion. Total turnover fell 13.8% overall, driven by a 10.5% decline in the medical sector and an 18.5% decline in the industrial sector.
Enrico Romagnoli
executiveLooking at Q2 2020, turnover trends differed between medical and industrial versus aesthetic when compared with Q1 2020, when the medical sector grew 7% ; in Q2 it was minus 25%, while the industrial sector dropped 44% in Q1 and grew 1% in Q2 2020. Within medical, the slight turnover contraction seen in the aesthetic and service segment — falling 8% and 7%, respectively — comes from the positive trend in Japan, one of the most important markets where the group operates. The surgery segment was also hit by the downturn, since all hospital activities suddenly focused on COVID patients. It posted revenues of EUR 19.9 million versus EUR 23.3 million in the same period of 2019, a reduction of 14%. The therapy segment recorded turnover of EUR 3.3 million versus EUR 5.4 million in the same period last year. The industrial sector showed a strong sales recovery in Q2 compared with Q1. The sector benefited in particular from the recovery in turnover in China; the sheet metal cutting segment, even though in the first 6-month 2020 we had a decline of 23%; and the very good performance of Cutlite Penta, thanks to a high level of demand and with the COVID effect limited to the period of forced closure.
Enrico Romagnoli
executiveActually, Cutlite Penta posted higher turnover during those 6 months. For the segment, total turnover across the 6 months came to EUR 49 million, versus EUR 58 million in the same stretch of last year — a decline of 16%. During Q1, the drop stood at roughly 50%. The market sector followed a pattern much like sheet metal cutting, though the fall was larger in the second quarter. H1 2020 turnover reached EUR 7.6 million, against EUR 9.2 million in H1 of last year, a reduction of 15%. Just as with system sales, after-sales service also experienced a notable slowdown. Turning to how revenues break down geographically, you can see that across the rest of the world industrial slipped because of China, whereas medical grew 1%, driven by excellent results in the Japanese and American markets. In Italy, industrial did well thanks to Cutlite Penta, while in medical, the halt of activity in the medical and professional beauty sector clearly brings a 37% contraction, with turnover of EUR 9.9 million versus EUR 15.8 million in H1 last year.
Enrico Romagnoli
executiveAcross Europe, both sectors were down, though medical held up better than industrial. Andrea, go ahead please.
Andrea Cangioli
executiveAll right, so up to now, to sum things up and give you, let's say, a sense of what's anticipated from us over the coming months, we can confirm that demand volumes are recovering gradually, and results along with them. And as I mentioned, those results are pretty satisfying considering the circumstances. Naturally, total demand volume hasn't yet gotten back to the levels seen last year. It also remains uncertain and unstable because of the restrictions in place and, above all, because of the uncertainties stemming from how the pandemic develops and its impact on the economy. So the overall market situation in which the group operates is still weak. Closing that gap with the 2019 results won't be possible. We expect sales volumes and operating results to be better in the second half than in the first half, though they will still fall short of the levels posted in 2019. Given the current market condition, and trusting there will be no additional repercussions or restrictions, we're aiming, for the full 2020 year, to keep the decline in turnover versus 2019 within 10%, with EBIT margin on sales improving in the second half relative to the first half. So thank you for joining us.
Andrea Cangioli
executiveThat wraps up our presentation, and now we're ready to take your questions.
Operator
operator<<operator_script>> Our initial question comes from François Robillard at Intermonte.
François Robillard
analystLet's start with guidance. The target itself is fairly clear. That said, could you give us a bit more detail on how the contained revenue decline is meant to be achieved? Specifically, relative to the H1 trends, what should we expect on a year-on-year basis in both medical and industrial, and which segments do you see performing better? You mentioned Cutlite Penta is doing quite well. Is that going to be the primary growth driver in the second half? And my second question goes back to what Andrea said about CapEx going forward — could you just remind us of your CapEx targets for expansion in the second half of the year and in 2021?
Enrico Romagnoli
executiveThanks, François, for that question. Regarding what we expect for the second half, you're right. On the revenue side, the rebound was far stronger in industrial than in medical. So we anticipate—and based on what we've observed so far—a very strong second half in the industrial business, which, when compared with 2019, will deliver better turnover results. We also anticipate a recovery in medical in absolute value. But naturally, we're up against a very, very demanding half, since the second half of 2019 was exceptionally brilliant in medical. That's why we plan for, and we know we will achieve, better results than in the first half. Yet, as I said earlier, matching the 2019 results will be very difficult. This will affect profitability as well, because, as in the second 3 months, industrial's recovery has been very strong—high volumes, but lower margins too. That's why the overall EBIT margin can't be expected to compare with the EBIT margin of the second half of 2019. On top of that, we will also be affected by the unfavorable movement in the foreign exchange rate with the U.S.
Enrico Romagnoli
executiveThe dollar dropped roughly 10 points. We were at about 1.1, and at this point we're at about 1.2. The U.S. has been a big market for us this year, and sadly this decline in the value of the U.S. dollar will hit our margins — not dramatically, of course, but it will hit them. On CapEx, I mentioned that this year we'd see a very large cut in CapEx. That's what's happening. My belief is that this year's CapEx in total won't exceed — it'll be slightly — it'll come in under EUR 10 million, though I'd expect something nearer EUR 7 million — somewhere between EUR 7 million and EUR 8 million. In 2021, real estate investments ought to slow down, but what I've just told you is that we have this extra EUR 5 million for the new Penta land, and that will hit H1 2021. So in 2021, total CapEx will probably be a bit above EUR 10 million.
François Robillard
analystI just want to circle back on that top-line guidance. Does that figure include the FX impact — meaning the foreign exchange effect is baked in?
Andrea Cangioli
executiveYeah. Yeah. Sure, absolutely. Regarding the top line — at the time we gave this guidance, we already knew about the dollar — I mean, our calculation assumes the dollar at 1.2.
Operator
operatorOur next question comes from Pierre Castela at GMP.
Pierre Castela
analystJust a quick question about receivables. How are things looking on that front? Are you seeing any worsening there? And in medical specifically, is it harder to get those bills paid?
Andrea Cangioli
executiveNo. We aren't seeing any abrupt shift in how receivables get collected. In fact, we took a more cautious tack when calculating reserves for uncollectable receivables. That approach also complied with guidance issued by the auditing principal body — I can't recall its name — but which, I mean, was appraised by ESMA. So there's more, let's say, allowance sitting in the depreciation, amortization and allowances line of the P&L, but so far we haven't encountered any genuine problem. As I mentioned earlier, I'm somewhat concerned about what could happen once all those moratoriums end. Several customers right now aren't paying their monthly installment to the leasing companies, because through a state, a government, let's say, resolution, the leasings and the banks aren't requesting the monthly installments. Initially it ran until September 30, now I believe it runs until January 31. So we live in a sort of bubble from this standpoint. This could particularly affect 1 segment where we operate, which is the professional beauty segment, and for that reason we were specifically, let's say, aggressive with the uncollectable receivable allowance in that particular sector.
Andrea Cangioli
executiveStill, in broad terms, I don’t view that as a major issue.
Operator
operatorKatharina Raatz from Berenberg has the next question.
Katharina Raatz
analystKatharina here, from Berenberg Asset Management. If I may, I have 3 questions. First, on operating leverage: unless I'm mistaken, the sales drop you posted in Q2 was about the same size as the one from Q1, yet operating leverage looks considerably stronger — so could you shed more light on why? Second, on inventory, which was the biggest driver behind the rise in net working capital, I'd also like a bit more detail about that inventory build. And third, on the pricing environment in industrial in China, I'm simply curious to understand better whether — yes — you now have to adjust to this new pricing level, and what your strategy looks like on that going forward?
Enrico Romagnoli
executiveAll right, thanks Katharina. On leverage — yes, you're correct that it was significantly higher during Q2, and the reason is that Q2 benefited enormously from a substantial reduction in our fixed cost base. We made heavy use of the payroll protection schemes, Cassa Integrazione, which brought down payroll expense across Italy, Germany, and France, and that lowered costs by a meaningful amount. On top of that, because we aren't operating at full capacity, we incurred lower expenses on management by objective, since the targets weren't achieved. We also spent less on overtime — employees simply aren't putting in extra hours. So the savings on employee expense were considerable. Beyond that, compared with a typical period, we saw big savings across all commercial costs, since no one was traveling and there were no congresses to attend — we were all stuck at home. So leverage — meaning fixed costs — came in far lower. Fixed costs should return to normal, or nearly normal, in Q3. As for payroll expense, it will remain somewhat below normal, because we still aren't running at full level.
Enrico Romagnoli
executiveEvery other piece of payroll cost will come down as well in Q3. And on top of that, commercial expenses are still going to be lower, even though we'll begin showing up at a few events — I mean, today we're at the Beijing Industrial Laser Fair, and next week we'll be at the Shanghai Industrial Fair. So things will start to pick up somewhat, but not yet at full scale. As a result, we managed to achieve the same outcome in absolute value, thanks to the very substantial savings across certain cost categories. Inventory. Inventory peaked at the end of Q1. In Q2 we saw a modest decrease. Even so, the levels remain fairly high, because this always happens: we hold inventory to build a particular item, then the customer puts that order on hold and asks for something different. That forces us to purchase goods in order to make products that weren't in the original schedule, while the longer-lead material sits in inventory for a longer time. Honestly, I don't foresee any genuine issue with inventory over the medium term. There is nothing we hold that we won't be able to use. Naturally, all of this rests on the assumption that activity returns to normal or near normal, and that we don't go back into any really severe lockdown scenario.
Enrico Romagnoli
executiveMoving to the third question about the pricing change in China. That pricing shift in China has been quite strong. Once the lockdown ended, we're producing at very high volumes but at lower prices. This was quite evident in the Q2 financials of our Chinese business, where we were able to sell and to have revenues higher than the corresponding quarter of 2019, but with a very low profitability. And we have various kinds of countermeasures. We, let's say, negotiated better terms for laser source purchase, and we will see a significant reduction in laser source costs in Q3 and Q4. And we launched a comprehensive cost reduction plan, which was actually launched in the very first days after the recovery, which will be effective with its results basically in Q4 2020. And so we hope and we count to have an increase of margins in the Chinese business from the lower level. We are now in Q4 and in H -- and in the second half of the year.
Katharina Raatz
analystGot it. I also realize this remains an ongoing challenge in China. Still, do you believe you can get back to those appealing EBIT margin levels you achieved in China before?
Andrea Cangioli
executiveSo I believe that provided the market stays where it is and we see solid reasons to expect that we can push volumes higher, we could once again benefit from a leverage effect and get back to profitability the way we were before. Still, we need healthy demand, because right now the Chinese business — with its 3, let's say, production sites and 4 factories — has to have meaningful volume in order to capture that leverage — the scale savings and the leverage.
Katharina Raatz
analystAll right, got it. And I apologize — just a single follow-up question. So did the opportunity, if you will, to capture that operating leverage shift? In other words, because of COVID-19, has the competitive landscape in China changed?
Andrea Cangioli
executiveWell, the competition has gotten tougher, I'd say. It also hinges on the mix. During Q2, we sold a quantity of systems that no quarter had seen from us before — not even Q4 2019. A few products we brought to market are entirely made in China. So those products that are entirely Chinese-made carry a lower margin. And even though sales rose for the higher-margin items — the hybrid systems, let's say, built in China but incorporating several European components — their contribution to the total shrank. On top of that, the rebound was exclusively Chinese, purely a Chinese, let's say, phenomenon. China accounted for roughly 10% of sales to neighboring countries last year. This year that share has likely fallen to 1%, since the recovery is a Chinese phenomenon. And because international sales shipped out of China carry larger — higher margins, this effect should swing back once we can get to different sales volumes in international sales. That process is underway. It's happening gradually. The Chinese rebound was extremely swift, whereas the recovery elsewhere in this regard was slower.
Andrea Cangioli
executiveStill, I do see a favorable direction — and just how favorable that direction turns out to be will hinge on how other economies keep bouncing back in their volumes and in their economies over the remainder of this year and then in 2021.
Operator
operatorOur next question is a follow-up from Pierre Castela at GMP.
Pierre Castela
analystYeah, apologies for that. I have 2 quick questions. First, regarding net capital employed of roughly EUR 200 million, could you give us a sense of how that capital employed breaks down between the 2 divisions? And second, given that we used up around EUR 35 million of cash during the first half, can you give us a sense of what you're expecting for the second half in terms of cash consumption or generation, factoring in the land acquisition and so on?
Andrea Cangioli
executiveNo. I’m not sure—maybe Rico can provide the figure. In the financials, I think there’s segment reporting that would give you the precise detail. I don’t have it with me here. I don’t have it memorized, but it’s available in the financial report. On cash generation, we think the second half, as usual—and in 2019 as well—should outperform the first half when it comes to generating cash. So we expect normal operations to produce an increase in the net financial position. EUR 5 million, EUR 10 million right now, really, under the current guidance, I’d say we could anticipate a EUR 5 million increase, but we truly aren’t in a position to model it precisely, because we also don’t know how sales will land and therefore how receivables and inventory will hit the P&L—and exactly when. I mean, whether it’s December or November would make a difference. But generally speaking, generally speaking, I see a positive trend. I see our strengths in the market. I see us returning to good cash generation in the second half.
Enrico Romagnoli
executiveThanks. When it comes to capital employed, that figure is larger than what we see in medical — roughly EUR 150 million — and versus industrial, it's about EUR 70 million, EUR 80 million, give or take.
Operator
operatorAndrea Bonfa from Banca Akros has the next question.
Andrea Bonfà
analystAndrea, I was wondering if you could share whatever insight you have regarding consumer sentiment around the world—say, among your clients in the medical and aesthetic space—specifically on how activity and treatments are picking back up. And of course, medical and aesthetics have taken a bigger hit from social distancing and all the measures used to contain the coronavirus pandemic. So if you could just expand on that point: do you believe the end customer—let's say—will take a while to come back, or is it our clients who are hesitant about placing orders at this moment? That's all for now.
Andrea Cangioli
executiveThanks for that question, Andrea. It's hard to give a precise answer, because I can tell you exactly what we observe, both where we sell direct and where we work through distributors — there's an interface there that isn't always fully transparent to us, so the customer's exact behavior is unknown to us. What we've seen here — several things have stood out in consumer behavior. First, a remarkable response from many of them, who rushed into aesthetic parlors to get treatments, willing to make — I mean, to respond to that lengthy lockdown period by spending more on aesthetics. And this is rather odd. The aesthetic sector gets less attention, for instance, than the therapy sector. Even though we read that, for instance, athletes right now are more hurt than usual, since after a few months of inactivity they're more exposed to injuries, our therapy sector has been suffering over the last month more than the aesthetic sector. In aesthetics, we saw consumption peaks, for instance, in Italy. In Italy, we did extremely well in the medical sector in July and also in August, which can only be explained by a very particular psychological reaction to the lockdown in the post-COVID era.
Andrea Cangioli
executiveBroadly around the globe, my sense is that this type of response is pretty common, yet even so, we are selling capital equipment. Consequently, for a physician to commit to an investment, that person has to feel somewhat more assured about what the near future holds. In Italy, my sense is that we feel fairly confident. Elsewhere—what I mean is that the outstanding restriction is still holding purchases down at the very same level seen 12 months ago. As for the surgical business, in theory we anticipate healthy demand behavior, since what I mean is that surgical procedures are not tied to anything that COVID has damaged. Whether someone has a kidney stone or someone has an enlarged prostate does not hinge on the economic cycle. Even so, there were also COVID hiccups here, because hospital structures are concentrated on COVID and at this moment, simply for several months, they gave no thought to other disciplines, and as a result they slowed purchases in other segments as well. My sense is that this will end sooner, because sooner then we will witness a complete recovery across other segments, since in fact the total focus on COVID will also fade, again, always barring a worsening of the situation.
Andrea Cangioli
executiveThis is pretty much what we're seeing right now.
Operator
operator<<operator_script>> Thank you, gentlemen — go ahead. We have no further questions right now.
Bianca Fersini Mastelloni
unknownThat means we’re able to wrap up the conference. Andrea?
Andrea Cangioli
executiveYes. So thanks, everyone, for joining. Over the coming weeks, we'll be taking part in a handful of conferences virtually. I'm aware that some of you have already signed up. If there are still — there are spots left. You can reach out to Bianca and — since we'll be around for one-on-one meetings at least a couple of times during the next week. Thanks once more for being on the call, and have a good day.
Enrico Romagnoli
executiveThanks.
Bianca Fersini Mastelloni
unknownMuch appreciated for all of it. Bye. Bye-bye, everybody. Bye.
Operator
operatorThank you for being with us, everyone. That brings this conference to a close. You can now hang up your phones. We appreciate your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.